EP3714885A4 - COMPOSITION FOR PREVENTING, RELIEVING OR TREATING DISEASES OF BONE LOSS, INCLUDING CYCLO (HIS-PRO) (CHP) - Google Patents

COMPOSITION FOR PREVENTING, RELIEVING OR TREATING DISEASES OF BONE LOSS, INCLUDING CYCLO (HIS-PRO) (CHP) Download PDF

Info

Publication number: EP3714885A4
Authority: EP; European Patent Office
Prior art keywords: chp; relieving; pro; preventing; composition
Prior art date: 2017-11-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP18879826.8A

Other languages

German (de)

French (fr)

Other versions

EP3714885B1 (en

EP3714885A2 (en

Inventor

Hoe Yune Jung

Heon Jong Lee

Do Hyun Lee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novmetapharma Co Ltd

Original Assignee

Novmetapharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-20

Filing date

2018-11-20

Publication date

2021-08-18

2018-11-20 Application filed by Novmetapharma Co Ltd filed Critical Novmetapharma Co Ltd

2020-09-30 Publication of EP3714885A2 publication Critical patent/EP3714885A2/en

2021-08-18 Publication of EP3714885A4 publication Critical patent/EP3714885A4/en

2024-07-31 Application granted granted Critical

2024-07-31 Publication of EP3714885B1 publication Critical patent/EP3714885B1/en

Status Active legal-status Critical Current

2038-11-20 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Zoology (AREA)
Virology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Botany (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Alternative & Traditional Medicine (AREA)
Inorganic Chemistry (AREA)
Medicines Containing Plant Substances (AREA)

EP18879826.8A 2017-11-20 2018-11-20 Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp) Active EP3714885B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20170154820		2017-11-20
PCT/KR2018/014275 WO2019098811A2 (en)	2017-11-20	2018-11-20	Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)

Publications (3)

Publication Number	Publication Date
EP3714885A2 EP3714885A2 (en)	2020-09-30
EP3714885A4 true EP3714885A4 (en)	2021-08-18
EP3714885B1 EP3714885B1 (en)	2024-07-31

Family

ID=66538798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18879826.8A Active EP3714885B1 (en)	2017-11-20	2018-11-20	Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)

Country Status (6)

Country	Link
US (1)	US11975041B2 (en)
EP (1)	EP3714885B1 (en)
JP (1)	JP6944221B2 (en)
KR (1)	KR102163445B1 (en)
CN (1)	CN111372586B (en)
WO (1)	WO2019098811A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102115353B1 (en) *	2019-05-17	2020-05-26	주식회사 노브메타파마	Composition comprising chp (cyclo-his pro) and pth for preventing, improving or treating of bone loss related disease
EP4199949A4 (en) *	2020-08-20	2024-10-16	NovMetaPharma Co., Ltd.	METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
KR102575908B1 (en) *	2020-12-11	2023-09-07	전남대학교산학협력단	Method for isolating cyclodipeptide-based compound derived from Lactobacillus sakei culture medium and composition for preventing or treating bone disease comprising the same
KR20250093685A (en)	2023-12-15	2025-06-25	주식회사 노브메타파마	Composition for improving exercise performance or muscular function, or preventing, ameliorating or treating muscle disease comprising cyclo-his pro(chp)
WO2025230339A1 (en) *	2024-04-30	2025-11-06	주식회사 노브메타파마	Use of cyclo-hispro alone or zinc and cyclo-hispro for inhibiting muscle loss or alleviating muscle function decline caused by anti-obesity drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2227658A (en) *	1989-02-03	1990-08-08	Cellana	Thyrotropin releasing hormone (trh) composition for enhancing immune function
US5418218A (en) *	1992-07-10	1995-05-23	The University Of Maryland At Baltimore	Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
DE4237456A1 (en) *	1992-11-06	1994-05-11	Merck Patent Gmbh	cyclopeptides
US5834032A (en) *	1997-08-11	1998-11-10	Song; Moon K.	Compositions and methods for treating diabetes
CA2345642A1 (en) *	1998-10-02	2000-04-13	Celtrix Pharmaceuticals, Inc.	Methods for the treatment of non-thyroid disorders
MXPA02001882A (en)	1999-08-23	2002-08-20	Univ Tulane	Modulation of the blood brain barrier transporter for leptin.
PL211976B1 (en)	2001-06-01	2012-07-31	Novartis Ag	Orally administering parathyroid hormone and calcitonin
US20070155664A1 (en)	2003-07-04	2007-07-05	Nycomed Danmark A/S	Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
CN100509008C (en) *	2004-04-12	2009-07-08	赵晓昂	Shutongfang for killing pain and preparation and use thereof
CN100548332C (en) *	2005-05-26	2009-10-14	赵晓昂	Compound extractive of general glycoside of Cape jasmine and preparation thereof and purposes
KR20080059430A (en)	2005-10-06	2008-06-27	나스텍 파마수티컬 컴퍼니 인코포레이티드	Parathyroid hormone formulations and methods of use
WO2007066841A1 (en)	2005-12-09	2007-06-14	Serombio Co., Ltd.	Yeast hydrolysate containing cyclo-his-pro and method for producing the same
CN101125201A (en)	2006-08-17	2008-02-20	石家庄欧意药业有限公司	Medicine composition for treating osteoporosis or preventing bone fracture caused by osteoporosis and its application
KR101530050B1 (en) *	2007-03-02	2015-06-22	주식회사 노브메타파마	Compositions and methods for treating Alzheimer's disease and dementia
KR100989174B1 (en)	2010-02-01	2010-10-20	(주)새롬바이오	Yeast hydrolysate having improved effect on female climacteric disorder and a food composition comprising thereof
KR101138714B1 (en)	2011-07-26	2012-04-24	(주)새롬바이오	Composition for damage-prevention and regeneration of chondrocytes containing yeast hydrolysate as an active ingredient
CN104971086B (en) *	2014-04-09	2020-12-08	台北医学大学	The use of salvia to promote bone formation or provide neuroprotection
KR102012554B1 (en)	2016-07-13	2019-08-23	주식회사 노브메타파마	Cytoprotective composition for protection of cell containing Cyclo His-Pro as Active Ingredient

2018
- 2018-11-20 JP JP2020527807A patent/JP6944221B2/en active Active
- 2018-11-20 WO PCT/KR2018/014275 patent/WO2019098811A2/en not_active Ceased
- 2018-11-20 US US16/764,913 patent/US11975041B2/en active Active
- 2018-11-20 CN CN201880074979.3A patent/CN111372586B/en active Active
- 2018-11-20 EP EP18879826.8A patent/EP3714885B1/en active Active
- 2018-11-20 KR KR1020180143641A patent/KR102163445B1/en active Active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REBECCA A SENDAK ET AL: "Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling", INTERNATIONAL ORTHOPAEDICS, SPRINGER, BERLIN, DE, vol. 31, no. 6, 5 July 2007 (2007-07-05), pages 753 - 757, XP019561115, ISSN: 1432-5195, DOI: 10.1007/S00264-007-0417-7 *

Also Published As

Publication number	Publication date
KR102163445B1 (en)	2020-10-07
US20200338156A1 (en)	2020-10-29
EP3714885B1 (en)	2024-07-31
CN111372586A (en)	2020-07-03
US11975041B2 (en)	2024-05-07
WO2019098811A2 (en)	2019-05-23
WO2019098811A3 (en)	2019-07-11
JP2021503483A (en)	2021-02-12
KR20190058346A (en)	2019-05-29
CN111372586B (en)	2023-07-25
JP6944221B2 (en)	2021-10-06
EP3714885A2 (en)	2020-09-30

Legal Events

Date	Code	Title	Description
2019-05-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-08-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-08-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-09-30	17P	Request for examination filed	Effective date: 20200619
2020-09-30	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-09-30	AX	Request for extension of the european patent	Extension state: BA ME
2021-02-24	DAV	Request for validation of the european patent (deleted)
2021-02-24	DAX	Request for extension of the european patent (deleted)
2021-06-11	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40037664 Country of ref document: HK
2021-08-18	A4	Supplementary search report drawn up and despatched	Effective date: 20210720
2021-08-18	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/4985 20060101AFI20210714BHEP Ipc: A61K 35/52 20150101ALI20210714BHEP Ipc: A61K 36/48 20060101ALI20210714BHEP Ipc: A23L 33/10 20160101ALI20210714BHEP Ipc: A23L 33/105 20160101ALI20210714BHEP Ipc: A61P 19/08 20060101ALI20210714BHEP Ipc: A61P 19/10 20060101ALI20210714BHEP
2023-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-04-26	17Q	First examination report despatched	Effective date: 20230324
2024-03-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-03-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-03-20	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/12 20060101ALI20240213BHEP Ipc: A61K 33/30 20060101ALI20240213BHEP Ipc: A61P 19/10 20060101ALI20240213BHEP Ipc: A61P 19/08 20060101ALI20240213BHEP Ipc: A23L 33/105 20160101ALI20240213BHEP Ipc: A23L 33/10 20160101ALI20240213BHEP Ipc: A61K 36/48 20060101ALI20240213BHEP Ipc: A61K 35/52 20150101ALI20240213BHEP Ipc: A61K 31/4985 20060101AFI20240213BHEP
2024-04-03	INTG	Intention to grant announced	Effective date: 20240304
2024-06-19	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2024-06-27	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2024-06-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2024-07-31	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-07-31	P01	Opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: APP_36815/2024 Effective date: 20240620
2024-07-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D
2024-08-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602018072588 Country of ref document: DE
2024-08-28	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-11-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2024-12-04	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20240731
2024-12-12	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241202
2024-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1707842 Country of ref document: AT Kind code of ref document: T Effective date: 20240731
2024-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241202
2025-01-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241031
2025-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241101 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-01-20	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-01-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241130
2025-01-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-01-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241031
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241031 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241031 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241130 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241101 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-04-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-04-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-04-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-05-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602018072588 Country of ref document: DE
2025-06-06	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2025-06-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2025-06-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-07-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-07-09	26N	No opposition filed	Effective date: 20250501
2025-07-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241120
2025-07-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-07-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241130
2025-08-28	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20241130
2025-09-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240731
2025-10-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241130
2025-10-20	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241130
2025-10-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241120
2026-01-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20251118 Year of fee payment: 8
2026-01-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20251118 Year of fee payment: 8
2026-03-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20181120
2026-03-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20181120

Publication	Publication Date	Title
EP3714885A4 (en)	2021-08-18	COMPOSITION FOR PREVENTING, RELIEVING OR TREATING DISEASES OF BONE LOSS, INCLUDING CYCLO (HIS-PRO) (CHP)
MX2020006128A (en)	2020-09-21	Inhibitors of fibroblast activation protein.
MX383652B (en)	2025-03-14	INTEGRATED STRESS PATHWAY MODULATORS.
MX2019014041A (en)	2020-09-25	MAGL PYRAZOLIC INHIBITORS.
MX377903B (en)	2025-03-10	SUBSTITUTED OXOPYRIDINE DERIVATIVES.
EP3448875A4 (en)	2020-04-08	COMPOSITIONS FOR THE TREATMENT OF DISEASES
LT3658140T (en)	2025-08-25	COMBINATIONS OF APROCITENTANE AND OTHER ACTIVE INGREDIENTS FOR THE TREATMENT OF RESISTANT HYPERTENSION
MA53835A (en)	2021-08-11	BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS FOR THE P.E. TREATMENT OF INFLAMMATORY DISEASES
EP3890725A4 (en)	2022-05-18	COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES
MX2018010374A (en)	2019-03-28	Inhibitors of wdr5 protein-protein binding.
MX392098B (en)	2025-03-21	POLIOMAVIRUS NEUTRALIZING ANTIBODIES.
GEP20227406B (en)	2022-08-25	Chromane monobactam compounds for the treatment of bacterial infections
MX2017009417A (en)	2017-12-07	Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
MA42366A (en)	2018-05-16	DEVICE TO TREAT, PREVENT OR REDUCE MYOPIA, OR THE RISK OF THEM
EP3292119A4 (en)	2018-10-03	DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
PH12016502347A1 (en)	2017-02-13	1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
EA201891610A1 (en)	2019-01-31	DERIVATIVES 3- (CARBOXYETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN
LT3886799T (en)	2023-12-27	COMPOSITION FOR THE TREATMENT OF HAIR LOSS
SG10201805646WA (en)	2018-08-30	Angiopoietin-like 4 antibodies and methods of use
EP3912483A4 (en)	2022-08-31	COMPOSITION COMPRISING PEDIOCOCCUS INOPINATUS FOR PREVENTING, RELIEVING OR TREATING NEURODEGENERATIVE DISEASES
EP3331356A4 (en)	2019-04-10	FRAGMENTS AND DERIVATIVES OF PROGRANULIN (PGRN) FOR THE TREATMENT OR RELIEF OF LYSOSOMAL DISEASES
MA32224B1 (en)	2011-04-01	(Pyrazolyl-carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases
MA50163A (en)	2020-07-29	COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF INFERTILITY AND SUB-FERTILITY
WO2016193945A3 (en)	2017-01-12	Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
EP3878454A4 (en)	2022-08-24	USE OF 3-O-SULFAMATE 16,16-DIMETHYL-D-HOMEQUILENINE FOR TREATING CANCER DISEASES